Prime Medicine (PRME) Share-based Compensation (2021 - 2026)

Prime Medicine's Share-based Compensation history runs 6 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• Quarterly Share-based Compensation fell 18.25% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (up 396.94% YoY) and the FY2025 annual result came in at $29.3 million, down 34.87% from the prior year.
• Share-based Compensation was $4.6 million for Q1 2026 at Prime Medicine, up from -$54.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $78.1 million in Q2 2025 and bottomed at -$54.5 million in Q4 2025.
• A 5-year average of $7.9 million and a median of $5.0 million in 2023 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 650.18% in 2024, while the deepest fall reached 700.97% in 2024.
• Prime Medicine's Share-based Compensation stood at $24.7 million in 2022, then plunged by 125.16% to -$6.2 million in 2023, then jumped by 608.93% to $31.6 million in 2024, then tumbled by 272.24% to -$54.5 million in 2025, then jumped by 108.52% to $4.6 million in 2026.
• Business Quant data shows PRME's Share-based Compensation at $4.6 million in Q1 2026, -$54.5 million in Q4 2025, and $78.1 million in Q2 2025.